The shortage timeline
| Date | Action |
|---|---|
| 2022 | Semaglutide added to FDA shortage list amid surging demand |
| Feb 2025 | FDA declares the semaglutide shortage resolved |
| 2025 | 503A/503B enforcement-discretion windows close |
| Apr 2026 | Proposed 503B bulks-list exclusion (sema, tirz, liraglutide) |
The safety signals
Most reports involve dosing errors from patients drawing doses out of multi-dose vials, with some requiring hospitalization, plus quality concerns from unverified sourcing. Salt-form active ingredients and counterfeit products have compounded the risk.
What is still legal
Patient-specific 503A compounding remains lawful when a licensed prescriber documents an individual clinical need that an FDA-approved product cannot meet — for example, a documented allergy to an inactive ingredient or a needed non-standard dose. Broad substitution for an available approved product on the basis of price is not a qualifying reason.
Approved alternatives now exist
The access argument for compounded semaglutide has weakened. Brand injectable Wegovy self-pay pricing has fallen, and an FDA-approved oral Wegovy pill launched in January 2026 near $149/month to start. For many patients, an approved product is now both accessible and verifiable — a meaningfully different situation than during the shortage.
How to lower your risk
If you use compounded semaglutide under a documented clinical need, confirm the pharmacy pathway (503A vs 503B), verify base-form active ingredient, request a certificate of analysis, confirm concentration and fill volume, and never self-adjust a vial dose without clinician guidance. See our side-effects management and provider-selection guides. If a product seems off, stop and consult a clinician.
Bottom line
Compounded semaglutide is no longer a mass-market product. It persists in narrow, documented circumstances, carries real safety considerations, and now competes with more affordable, FDA-approved options. Weigh those factors with a licensed clinician rather than defaulting to a compounded route out of habit.
Making the decision today
If you are currently on compounded semaglutide, this is a reasonable moment to revisit the choice with a clinician rather than renewing on autopilot. The three questions worth answering are whether you have a documented clinical reason that an approved product cannot meet, whether an FDA-approved option (injectable or the new oral pill) is now accessible and affordable for you, and whether your current provider can verify base-form sourcing, pharmacy pathway, and quality testing. If the honest answers point toward an approved product, switching may reduce both regulatory and safety uncertainty. If a documented need genuinely favors compounding, insist on the transparency markers above. Either way, the decision should be deliberate and clinician-guided, not driven by habit or by whichever option was cheapest during the shortage.
Frequently asked questions
Is compounded semaglutide still available in 2026?
Only through narrow patient-specific 503A pathways with documented clinical need. Large-scale compounding lost its legal basis after the shortage resolved in February 2025.
How many adverse events were reported?
As of early 2025, the FDA logged 455+ reports tied to compounded semaglutide, many involving dosing errors from multi-dose vials.
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved regardless of the pharmacy, and shortage status does not change approval status.
Are there approved alternatives now?
Yes. Injectable Wegovy self-pay pricing has fallen and an FDA-approved oral Wegovy pill launched in January 2026, giving patients verified options.
References
- FDA. Clarifies policies for compounders as national GLP-1 supply stabilizes. 2025.
- FDA. Press materials on compounded GLP-1 adverse events. 2026.
- Pharmacy Times. FDA moves to close the door on compounded GLP-1s. 2026.
- 21 U.S. Code § 353a and § 353b.